

Supplement 3. Primary and secondary outcome per month – Surgical

Month	Pre-implementation N = 1470						Post-implementation N = 1545					
	Total episodes	Total doses	Withheld inappropriately n (%)	95% Confidence Interval	Total withheld n (%)	95% Confidence Interval	Total episodes	Total doses	Withheld inappropriately n (%)	95% Confidence Interval	Total withheld n (%)	95% Confidence Interval
1	29	90	21 (23.3)	15.1-33.4	30 (33.3)	23.7-44.1	28	108	5 (4.6)	1.5-10.5	17 (15.7)	9.4-24.0
2	30	129	12 (9.2)	4.9-15.7	28 (21.7)	14.9-29.8	30	125	1 (0.8)	0.0-4.4	18 (14.4)	8.8-21.8
3	29	82	14 (17.1)	9.7-27.0	19 (23.2)	14.6-33.8	28	108	17 (15.7)	9.4-24.0	23 (21.3)	14.0-30.2
4	30	99	12 (12.1)	6.4-20.0	33 (33.3)	24.2-43.5	29	99	1 (1.0)	0.0-5.5	15 (15.2)	8.7-23.8
5	28	95	5 (5.3)	1.7-12.0	15 (15.8)	9.1-24.7	29	141	1 (0.7)	0.0-3.9	21 (14.9)	9.5-21.9
6	29	95	3 (3.2)	0.7-9.0	13 (13.7)	7.5-22.3	29	155	7 (4.5)	1.8-9.1	20 (12.9)	8.1-19.2
7	29	125	10 (8.0)	3.9-14.2	20 (16.0)	10.1-23.6	29	131	8 (6.1)	2.7-11.7	24 (18.3)	12.1-26.0
8	28	131	9 (6.8)	3.1-12.5	25 (19.1)	12.7-26.9	29	101	4 (4.0)	1.1-9.8	26 (25.7)	17.6-35.4
9	30	101	8 (7.9)	3.6-5.3	24 (23.8)	15.9-33.3	27	138	15 (10.9)	6.2-17.3	30 (21.7)	15.2-29.6
10	28	107	8 (7.5)	3.3-14.2	23 (21.5)	14.1-30.5	29	123	5 (4.1)	1.3-9.2	16 (13.0)	7.6-20.3
11	28	132	14 (10.6)	5.9-17.2	18 (13.6)	8.3-20.7	29	99	8 (8.1)	3.6-15.3	24 (24.2)	16.2-33.9
12	29	135	14 (10.4)	5.8-16.8	26 (19.3)	13.0-26.9	28	91	5 (5.5)	1.8-12.4	14 (15.4)	8.7-24.5
13	29	149	22 (14.8)	9.5 (21.5)	34 (22.8)	16.3-30.4	29	126	17 (13.5)	8.1-20.7	36 (28.6)	20.9-37.3